Cell-Based Therapy for Ischemic Heart Disease: A Clinical Update

Jeremy L. Herrmann, Aaron M. Abarbanell, Brent R. Weil, Yue Wang, Meijing Wang, Jiangning Tan, Daniel R. Meldrum

Research output: Contribution to journalReview article

40 Scopus citations

Abstract

Progenitor cell therapy is a promising treatment for ischemic heart disease. Early clinical trials of autologous bone marrow-derived progenitor cell therapy for acute and chronic myocardial ischemia showed modest functional improvements after cell delivery; however, the duration of these benefits remains unclear. Ongoing investigations continue to enhance our understanding of the mechanisms by which progenitor and stem cells function and how their survival and cardioprotective abilities can be improved. This review discusses: (1) relevant progenitor and stem cells in myocardial regenerative therapy, (2) routes of cell delivery to ischemic myocardium, (3) clinical trials investigating bone marrow-derived progenitor cell therapy for myocardial ischemia, and (4) future directions of the field.

Original languageEnglish (US)
Pages (from-to)1714-1722
Number of pages9
JournalAnnals of Thoracic Surgery
Volume88
Issue number5
DOIs
StatePublished - Nov 1 2009

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Cell-Based Therapy for Ischemic Heart Disease: A Clinical Update'. Together they form a unique fingerprint.

  • Cite this